Nima Hamidi
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Nima Hamidi has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- Anthony R. MacLean
Department of Surgery, University of Calgary, Calgary, Alberta, Canada
1 shared publication - Ashley N. Clarke
IBD Unit, Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, Alberta, Canada
1 shared publication - Cathy Lu
Division of Gastroenterology and Hepatology, Department of Medicine, University of Calgary, Calgary, AB, Canada
1 shared publication - Christine Wang
Department of Surgery, University of Calgary, Calgary, Alberta, Canada
1 shared publication - Christopher Ma
Division of Gastroenterology & Hepatology, Department of Medicine, Cumming School of Medicine, University of Calgary , Calgary, Alberta
1 shared publication - Cynthia H. Seow
Division of Gastroenterology and Hepatology, Departments of Medicine and Community Health Sciences, University of Calgary, Calgary, Alberta, Canada
1 shared publication
Latest Publications
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Comparative Real-World Effectiveness of Biologic Therapies for Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
BACKGROUND: Postoperative recurrence is common after ileocolonic resection for Crohn's disease (CD). Comparative effectiveness data for advanced treatments for preventing recurrence are limited. METHODS: We conducted a population-based retrospective cohort study of adults with CD undergoing ileocolonic resection with primary anastomosis in the Calgary Health Zone, Canada (2016–2020). The primary outcome was endoscopic recurrence within 18 months, assessed using the modified Rutgeerts score as an ordinal endpoint. High-risk recurrence (modified Rutgeerts score ≥ i2b) was evaluated as a secondary outcome. Propensity scores were estimated using established clinical risk factors, and inverse probability of treatment weighting targeting the average treatment effect among treated patients was applied to ordinal and logistic regression models. Treatment effects were expressed as adjusted odds ratios (aOR) with 95% CI. RESULTS: Among 231 patients, 126 (54.5%) received biologic prophylaxis and 92 (39.8%) received no treatment; endoscopy was performed in 217 patients. High-risk endoscopic recurrence occurred in 42.3% (36/85) of untreated patients compared with 9.4% (6/64) receiving tumor necrosis factor (TNF) antagonists, 27.8% (10/36) receiving ustekinumab, and 9.5% (2/21) receiving vedolizumab. After weighting for established risk factors for recurrence, all biologic strategies were associated with reduced odds of endoscopic recurrence compared with no treatment (aOR 0.15–0.31, all P < 0.05). Vedolizumab was associated with lower odds of recurrence compared with ustekinumab (aOR 0.24 [0.06–0.92], P = 0.04) but not TNF antagonists (aOR 0.43 [0.10–1.87], P = 0.26). DISCUSSION: In this real-world cohort, biologic prophylaxis is associated with reduced endoscopic recurrence in CD. Both ustekinumab and vedolizumab are effective options, including after prior TNF exposure.
- 18 September 2026
- Published by Wolters Kluwer Health in American Journal of Gastroenterology
Comparative Real-World Effectiveness of Biologic Therapies for Preventing Postoperative Endoscopic Recurrence of Crohn's Disease
BACKGROUND: Postoperative recurrence is common after ileocolonic resection for Crohn's disease (CD). Comparative effectiveness data for advanced treatments for preventing recurrence are limited. METHODS: We conducted a population-based retrospective cohort study of adults with CD undergoing ileocolonic resection with primary anastomosis in the Calgary Health Zone, Canada (2016–2020). The primary outcome was endoscopic recurrence within 18 months, assessed using the modified Rutgeerts score as an ordinal endpoint. High-risk recurrence (modified Rutgeerts score ≥ i2b) was evaluated as a secondary outcome. Propensity scores were estimated using established clinical risk factors, and inverse probability of treatment weighting targeting the average treatment effect among treated patients was applied to ordinal and logistic regression models. Treatment effects were expressed as adjusted odds ratios (aOR) with 95% CI. RESULTS: Among 231 patients, 126 (54.5%) received biologic prophylaxis and 92 (39.8%) received no treatment; endoscopy was performed in 217 patients. High-risk endoscopic recurrence occurred in 42.3% (36/85) of untreated patients compared with 9.4% (6/64) receiving tumor necrosis factor (TNF) antagonists, 27.8% (10/36) receiving ustekinumab, and 9.5% (2/21) receiving vedolizumab. After weighting for established risk factors for recurrence, all biologic strategies were associated with reduced odds of endoscopic recurrence compared with no treatment (aOR 0.15–0.31, all P < 0.05). Vedolizumab was associated with lower odds of recurrence compared with ustekinumab (aOR 0.24 [0.06–0.92], P = 0.04) but not TNF antagonists (aOR 0.43 [0.10–1.87], P = 0.26). DISCUSSION: In this real-world cohort, biologic prophylaxis is associated with reduced endoscopic recurrence in CD. Both ustekinumab and vedolizumab are effective options, including after prior TNF exposure.